ReviewThe journal of venomous animals and toxins including tropical diseases2020
Chronic venous ulcers: a review on treatment with fibrin sealant and prognostic advances using proteomic strategies.
Review in The journal of venomous animals and toxins including tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Bacterial cellulose an effective material in the treatment of chronic venous ulcers of the lower limbs.Journal of materials science. Materials in medicine · 2021Trial
- Treatment of Chronic Venous Ulcers With Heterologous Fibrin Sealant: A Phase I/II Clinical Trial.Frontiers in immunology · 2021Trial
- Wound fluid proteomics reveal elevated alpha-1 antitrypsin levels are associated with healing of medical device related pressure injury.Clinical proteomics · 2026Article
- Heterologous Fibrin Biopolymer as a Key Scaffold for Bone Regeneration: Synergistic Effects with Photobiomodulation and Membrane Therapy.Gels (Basel, Switzerland) · 2026Article
- Efficacy of Three-Dimensional Bioactive Composites in Long Bone Repair with Photobiomodulation.Materials (Basel, Switzerland) · 2025Article
- Biofunctional response of a synthetic ceramic of 99.9% tricalcium phosphate associated with a heterologous fibrin biopolymer and infrared photobiomodulation.Frontiers in bioengineering and biotechnology · 2025Article
- Heterologous fibrin biopolymer as an emerging approach to peripheral nerve repair: a scoping review.The journal of venomous animals and toxins including tropical diseases · 2024Article
- Heterologous Platelet-Rich Plasma in the Treatment of Severe Skin Damage.Reports (MDPI) · 2023Article
- Ischemia Impaired Wound Healing Model in the Rat-Demonstrating Its Ability to Test Proangiogenic Factors.Biomedicines · 2023Article
- Tissue Bioengineering with Fibrin Scaffolds and Deproteinized Bone Matrix Associated or Not with the Transoperative Laser Photobiomodulation Protocol.Molecules (Basel, Switzerland) · 2023Article
- Antineoplastic properties and pharmacological applications of Crotalus durissus terrificus snake venom.Revista da Sociedade Brasileira de Medicina Tropical · 2022Review
- A biocomplex to repair experimental critical size defects associated with photobiomodulation therapy.The journal of venomous animals and toxins including tropical diseases · 2022Article
- Launching a CDMO in Brazil aiming to develop biopharmaceuticals for clinical trials.The journal of venomous animals and toxins including tropical diseases · 2022Article
- Fibrin Biopolymer Incorporated with Antimicrobial Agents: A Proposal for Coating Denture Bases.Materials (Basel, Switzerland) · 2021Article
- Photobiomodulation Therapy on the Guided Bone Regeneration Process in Defects Filled by Biphasic Calcium Phosphate Associated with Fibrin Biopolymer.Molecules (Basel, Switzerland) · 2021Article
- Neuroactive venom compounds obtained fromThe journal of venomous animals and toxins including tropical diseases · 2021Article
- Fibrin biopolymer sealant and aquatic exercise association for calcaneal tendon repair.Acta cirurgica brasileira · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous ulcers are the main causes of chronic lower-limb ulcers. The healing difficulties encourage the research and development of new products in order to achieve better therapeutic results. Fibrin sealant is one of these alternatives. Besides being a validated scaffold and drug delivery system, it possesses excellent healing properties. This review covered the last 25 years of the literature and showed that the fibrin sealant is used in various clinical situations to promote the healing of different types of ulcers, especially chronic ones. These are mostly venous in origin and usually does not respond to conventional treatment. Commercially, only the homologous fibrin sealants obtained from human blood are available, which are highly efficient but very expensive. The heterologous fibrin sealant is a non-commercial experimental low-cost product and easily produced due to the abundance of raw material. The phase I/II clinical trial is already completed and showed that the product is safe and promisingly efficacious for the treatment of chronic venous ulcers. In addition, clinical proteomic strategies to assess disease prognosis have been increasingly used. By analyzing liquid samples from the wounds through proteomic strategies, it is possible to predict before treatment which ulcers will evolve favorably and which ones will be difficult to heal. This prognosis is only possible by evaluating the expression of isolated proteins in exudates and analysis using label-free strategies for shotgun. Multicentric clinical trials will be required to evaluate the efficacy of fibrin sealant to treat chronic ulcers, as well as to validate the proteomic strategies to assess prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.